Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Moderate Plaque Psoriasis Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

NCT03848871
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

NCT03875482
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Placebo solution for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

NCT00601107
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Doxercalciferol, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Hot Springs, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2014 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

NCT03635099
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo (fasted), BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted), BI 200 mg (fasted), Placebo (fed), BI 400 mg once daily (fed), BI 200 mg twice daily, 400 mg total (fed)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
Apremilast, Etanercept, Placebo tablet, Placebo injection
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 4 Interventional

Combination of Sotyktu and Enstilar for Plaque Psoriasis

NCT06329258
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar, Deucravacitinib
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

NCT02785185
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion, Ultravate Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
13
States / cities
Rogers, Arkansas • Beverly Hills, California • Carlsbad, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

NCT03837743
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DUR-928 Topical Solution, Vehicle Topical Solution
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

NCT02872285
View directory record Official record
Conditions
Psoriasis
Interventions
Drug: LYC-30937-EC, Placebo
Drug
Lead sponsor
Lycera Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Carmel, Indiana • Andover, Massachusetts • Fridley, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

NCT02618759
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Results available

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03573323
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab, Guselkumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Jun 7, 2026, 7:59 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

NCT03835481
View directory record Official record
Conditions
Psoriasis
Interventions
BI 730357, Placebo to match BI 730357
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Jun 7, 2026, 7:59 AM EDT
Terminated Phase 2 Interventional Results available

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

NCT03179605
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Madera, California • Santa Ana, California • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

NCT03895372
View directory record Official record
Conditions
Psoriasis
Interventions
PF-06826647 or Placebo, PF-06826647
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

NCT03337022
View directory record Official record
Conditions
Psoriasis
Interventions
CC-90006, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Anaheim, California • Fair Lawn, New Jersey • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

NCT00658788
View directory record Official record
Conditions
Psoriasis
Interventions
clobetasol propionate spray 0.05%, calcitriol ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Jun 7, 2026, 7:59 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

NCT02502188
View directory record Official record
Conditions
Parapsoriasis, Healthy Volunteers
Interventions
CC-90005, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

NCT02826603
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab, Ustekinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
123
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 2 Interventional

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

NCT00504270
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, RG3421 120mg, RG3421 20mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

NCT01777191
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab Auto-Injector, Ixekizumab Prefilled Syringe
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Anaheim, California • Bakersfield, California • Santa Monica, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

NCT03167515
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
074-6751 Lotion
Device
Lead sponsor
Ferndale Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
5
States / cities
Tampa, Florida • Carmel, Indiana • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

NCT05600036
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ESK-001, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jun 7, 2026, 7:59 AM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

NCT01384630
View directory record Official record
Conditions
Psoriasis
Interventions
RA-18C3
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jun 7, 2026, 7:59 AM EDT
Recruiting Phase 3 Interventional

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Deucravacitinib, Ustekinumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
3,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
122
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 7, 2026, 7:59 AM EDT